TCW Fund Exits Teva After Shares Outgrow Its Valuation Tests
The fund cited Teva’s share appreciation, branded-drug growth and improved margins as it explained its second-quarter exit.
Makkler Newsroom · Oct 1, 04:35 PM · 1 min read
Market closed· · ILA · Data may be delayed
Avg. target ILA 16,342.99 (+17.4%)
Prices may be delayed and are for informational purposes only - not investment advice.
Profitability and valuation from the filed statements
Answers from price, statements, peer and news data. Not investment advice.
MakklerAI Q&A is open to MakklerPRO members. Upgrade to MakklerPRO